GlassScriptPhysician profile
Kyle K Carter
NPI 1528002797
$14,485.26
in general payments reported to CMS, 2019-2025
58 companies · $2,002 in 2025
The $2,002 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,078 · 2020: $1,730 · 2021: $3,645 · 2022: $1,592 · 2023: $1,841 · 2024: $1,598 · 2025: $2,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,441.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,702.18 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Biohaven Pharmaceuticals, INC. | $1,413.21 | 2020-2021 | |
| Novo Nordisk INC | $1,300.65 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $1,013.33 | 2019-2025 | |
| Glaxosmithkline, LLC. | $953.82 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $791.69 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $653.11 | 2019-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $629.13 | 2019-2023 | |
| Lilly USA, LLC | $544.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $422.18 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $420.40 | 2019-2024 | Steglatro, Belsomra, Steglujan |
| Abbott Laboratories | $393.21 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $327.61 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.55 | 2019-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $293.19 | 2019-2025 | Rexulti |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $288.23 | 2019-2023 | Trintellix |
| Corcept Therapeutics | $281.74 | 2024-2025 | Korlym |
| Dexcom, INC. | $250.05 | 2021-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Zimmer Biomet Holdings, INC. | $222.51 | 2021-2022 | |
| Allergan, INC. | $195.47 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $191.41 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $159.06 | 2021-2025 | Veozah |
| Eisai INC. | $141.21 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $135.77 | 2019-2025 | Zoryve, Livalo |
| Biohaven Pharmaceutical Holding Company LTD. | $122.66 | 2022 | |
| Exact Sciences Corporation | $121.07 | 2024-2025 | Cologuard Collection Kit |
| Optos, INC. | $118.36 | 2020-2021 | |
| Corium, LLC | $97.40 | 2022-2025 | Azstarys, Azstarys |
| Arbor Pharmaceuticals, INC. | $95.72 | 2019-2021 | |
| Shield Therapeutics INC | $91.47 | 2024 | |
| Currax Pharmaceuticals LLC | $71.03 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $63.93 | 2023-2024 | Qelbree, Qelbree |
| Medtronic, INC. | $52.51 | 2021-2024 | Intellis Adaptivestim |
| Phathom Pharmaceuticals, INC. | $48.60 | 2023-2024 | Voquezna |
| Madrigal Pharmaceuticals | $39.46 | 2025 | Rezdiffra |
| Axsome Therapeutics, INC. | $37.68 | 2023-2025 | Auvelity |
| Lundbeck LLC | $37.60 | 2025 | Rexulti |
| Ironwood Pharmaceuticals, INC | $34.90 | 2020 | |
| Abiomed | $32.83 | 2025 | |
| Si-Bone, INC. | $32.76 | 2021 | |
| Neos Therapeutics, LP | $31.98 | 2021 | |
| Esperion Therapeutics, INC. | $30.59 | 2020-2021 | |
| Sanofi Pasteur INC. | $30.46 | 2019 | |
| Therapeuticsmd, INC. | $26.51 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $26.45 | 2019 | |
| Alexion Pharmaceuticals, INC. | $24.77 | 2022 | |
| Electromed, INC. | $19.59 | 2021 | |
| Inspire Medical Systems, INC. | $19.13 | 2023 | Inspire |
| Bausch Health US, LLC | $17.77 | 2020 | |
| Genentech USA, INC. | $17.68 | 2020 | |
| Lucid Diagnostics INC. | $16.51 | 2025 | |
| Dermira, INC. | $15.65 | 2020 | |
| Boston Scientific Corporation | $15.26 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.79 | 2019 | |
| Angiodynamics, INC. | $14.70 | 2020 | |
| Mylan Specialty L.P. | $14.62 | 2021 | |
| Intuity Medical INC | $12.70 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Aytu Biopharma, INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.